Oesophageal cancer
EC Smyth, J Lagergren, RC Fitzgerald… - Nature reviews Disease …, 2017 - nature.com
Oesophageal cancer is the sixth most common cause of cancer-related death worldwide
and is therefore a major global health challenge. The two major subtypes of oesophageal …
and is therefore a major global health challenge. The two major subtypes of oesophageal …
Heating technology for malignant tumors: A review
The therapeutic application of heat is very effective in cancer treatment. Both hyperthermia,
ie, heating to 39–45° C to induce sensitization to radiotherapy and chemotherapy, and …
ie, heating to 39–45° C to induce sensitization to radiotherapy and chemotherapy, and …
Diagnosis and management of Barrett's esophagus: an updated ACG guideline
Barrett's esophagus (BE) is a common condition associated with chronic gastroesophageal
reflux disease. BE is the only known precursor to esophageal adenocarcinoma, a highly …
reflux disease. BE is the only known precursor to esophageal adenocarcinoma, a highly …
ACG clinical guideline: diagnosis and management of Barrett's esophagus
NJ Shaheen, GW Falk, PG Iyer… - Official journal of the …, 2016 - journals.lww.com
Barrett's esophagus (BE) is among the most common conditions encountered by the
gastroenterologist. In this document, the American College of Gastroenterology updates its …
gastroenterologist. In this document, the American College of Gastroenterology updates its …
Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement
B Weusten, R Bisschops, E Coron, M Dinis-Ribeiro… - …, 2017 - thieme-connect.com
Current practices for the management of Barrett's esophagus (BE) vary across Europe, as
several national European guidelines exist. This Position Statement from the European …
several national European guidelines exist. This Position Statement from the European …
[HTML][HTML] Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial
Summary Background Treatment of dysplastic Barrett's oesophagus prevents progression to
adenocarcinoma; however, the optimal diagnostic strategy for Barrett's oesophagus is …
adenocarcinoma; however, the optimal diagnostic strategy for Barrett's oesophagus is …
AGA clinical practice update on endoscopic treatment of Barrett's esophagus with dysplasia and/or early cancer: expert review
P Sharma, NJ Shaheen, D Katzka, JJ Bergman - Gastroenterology, 2020 - Elsevier
Description The purpose of this best practice advice article is to describe the role of Barrett's
endoscopic therapy (BET) in patients with Barrett's esophagus (BE) with dysplasia and/or …
endoscopic therapy (BET) in patients with Barrett's esophagus (BE) with dysplasia and/or …
The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial
C Bureau, D Thabut, C Jezequel… - Annals of internal …, 2021 - acpjournals.org
Background: The efficacy of rifaximin in the secondary prevention of overt hepatic
encephalopathy (HE) is well documented, but its effectiveness in preventing a first episode …
encephalopathy (HE) is well documented, but its effectiveness in preventing a first episode …
Barrett's esophagus
SJ Spechler, RF Souza - New England Journal of Medicine, 2014 - Mass Medical Soc
Barrett's Esophagus | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …
Oesophageal cancer
J Lagergren, E Smyth, D Cunningham, P Lagergren - The Lancet, 2017 - thelancet.com
Oesophageal cancer is a clinically challenging disease that requires a multidisciplinary
approach. Extensive treatment might be associated with a considerable decline in health …
approach. Extensive treatment might be associated with a considerable decline in health …